⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16707273 | 1.00 | — | — | |
| SCHEMBL608371 | 1.00 | — | — | |
| SCHEMBL4420375 | 1.00 | — | — | |
| SCHEMBL23181030 | 1.00 | — | — | |
| SCHEMBL1425304 | 1.00 | — | — | |
| SCHEMBL23273618 | 1.00 | — | — | |
| SCHEMBL10098563 | 1.00 | — | — | |
| SCHEMBL12964371 | 1.00 | — | — | |
| SCHEMBL2621328 | 1.00 | — | — | |
| SCHEMBL4273375 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045595-A1 | N6 heterocyclic 8-modified adenosine derivatives | ZABLOCKI JEFF A (US) | 2002-04-18 | — | — | US | claimed |
| EP-4399980-A1 | HEART DISEASE AGENT AND METHOD FOR IMPROVING HEART DISEASE | Mirailab Bioscience Inc. (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20230279170-A1 | CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2023-09-07 | — | — | US | disclosed |
| US-20230255996-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-03 | — | — | US | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-11571436-B2 | Oral formulations of cytidine analogs and methods of use thereof | CELGENE CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
| EP-3889602-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2021-10-06 | — | — | EP | disclosed |
| WO-2021144475-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2021-07-22 | — | — | WO | disclosed |
| US-20170204101-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | HANDOK INC. (KR) | 2017-07-20 | — | — | US | disclosed |
| WO-2017079195-A1 | NICOTINAMIDE RIBOSIDE AND NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES FOR USE IN THE TREATMENTS OF MITOCHONDRIAL-RELATED DISEASES | MITOBRIDGE, INC. (US) | 2017-05-11 | — | — | WO | disclosed |
| EP-2663548-B1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9580428-B2 | Compositions and methods for inhibiting viral polymerase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| WO-2012099755-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| US-8129357-B2 | N6-(4-hydroxybenzyl)adenosine; Gastrodia extract; neurodegenerative Huntington's disease; trinucleotide repeat disease; hypoglycemic; neurological antiinflammatory; amination of 6-chloropurine ribonucleoside with 4-hydroxybenzylamine; condensation of adenosine with 4-methoxybenzoyl chloride | ACADEMIA SINICA (TW) | 2012-03-06 | — | — | US | disclosed |
| US-7824851-B2 | With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region | IDENIX PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090270431-A1 | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2009-10-29 | — | — | US | disclosed |
| EP-1947092-A1 | NUCLEIC ACID BASE HAVING PERFLUOROALKYL GROUP AND METHOD FOR PRODUCING THE SAME | Tosoh Corporation (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-20020045595-A1 | N6 heterocyclic 8-modified adenosine derivatives | ZABLOCKI JEFF A (US) | 2002-04-18 | — | — | US | disclosed |